BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 10515452)

  • 1. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group.
    Shand N; Weber F; Mariani L; Bernstein M; Gianella-Borradori A; Long Z; Sorensen AG; Barbier N
    Hum Gene Ther; 1999 Sep; 10(14):2325-35. PubMed ID: 10515452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.
    Eck SL; Alavi JB; Alavi A; Davis A; Hackney D; Judy K; Mollman J; Phillips PC; Wheeldon EB; Wilson JM
    Hum Gene Ther; 1996 Aug; 7(12):1465-82. PubMed ID: 8844206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.
    Rainov NG
    Hum Gene Ther; 2000 Nov; 11(17):2389-401. PubMed ID: 11096443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.
    Prados MD; McDermott M; Chang SM; Wilson CB; Fick J; Culver KW; Van Gilder J; Keles GE; Spence A; Berger M
    J Neurooncol; 2003 Dec; 65(3):269-78. PubMed ID: 14682377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The biosafety of the HSV-TK/GCV gene therapy in five cases of recurrent glioblastoma multiforme].
    Adachi N; Könü DL; Frei K; Yonekawa Y
    No Shinkei Geka; 2000 Nov; 28(11):965-74. PubMed ID: 11127592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
    Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
    Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration.
    Packer RJ; Raffel C; Villablanca JG; Tonn JC; Burdach SE; Burger K; LaFond D; McComb JG; Cogen PH; Vezina G; Kapcala LP
    J Neurosurg; 2000 Feb; 92(2):249-54. PubMed ID: 10659011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration.
    Niranjan A; Moriuchi S; Lunsford LD; Kondziolka D; Flickinger JC; Fellows W; Rajendiran S; Tamura M; Cohen JB; Glorioso JC
    Mol Ther; 2000 Aug; 2(2):114-20. PubMed ID: 10947938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma.
    Klatzmann D; Valéry CA; Bensimon G; Marro B; Boyer O; Mokhtari K; Diquet B; Salzmann JL; Philippon J
    Hum Gene Ther; 1998 Nov; 9(17):2595-604. PubMed ID: 9853526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The HSV-TK/GCV gene therapy in five cases of recurrent glioblastoma multiforme].
    Adachi N; Könü DL; Frei K; Yonekawa Y
    No Shinkei Geka; 2000 Oct; 28(10):865-71. PubMed ID: 11070906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy.
    Izquierdo M; Martín V; de Felipe P; Izquierdo JM; Pérez-Higueras A; Cortés ML; Paz JF; Isla A; Blázquez MG
    Gene Ther; 1996 Jun; 3(6):491-5. PubMed ID: 8789798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors.
    Kun LE; Gajjar A; Muhlbauer M; Heideman RL; Sanford R; Brenner M; Walter A; Langston J; Jenkins J; Facchini S
    Hum Gene Ther; 1995 Sep; 6(9):1231-55. PubMed ID: 8527482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.
    Westphal M; Ylä-Herttuala S; Martin J; Warnke P; Menei P; Eckland D; Kinley J; Kay R; Ram Z;
    Lancet Oncol; 2013 Aug; 14(9):823-33. PubMed ID: 23850491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.
    Oldfield EH; Ram Z; Culver KW; Blaese RM; DeVroom HL; Anderson WF
    Hum Gene Ther; 1993 Feb; 4(1):39-69. PubMed ID: 8384892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study.
    Harsh GR; Deisboeck TS; Louis DN; Hilton J; Colvin M; Silver JS; Qureshi NH; Kracher J; Finkelstein D; Chiocca EA; Hochberg FH
    J Neurosurg; 2000 May; 92(5):804-11. PubMed ID: 10794295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.
    Germano IM; Fable J; Gultekin SH; Silvers A
    J Neurooncol; 2003 Dec; 65(3):279-89. PubMed ID: 14682378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses.
    Sandmair AM; Loimas S; Puranen P; Immonen A; Kossila M; Puranen M; Hurskainen H; Tyynelä K; Turunen M; Vanninen R; Lehtolainen P; Paljärvi L; Johansson R; Vapalahti M; Ylä-Herttuala S
    Hum Gene Ther; 2000 Nov; 11(16):2197-205. PubMed ID: 11084677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.
    Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N
    Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells.
    Berenstein M; Adris S; Ledda F; Wolfmann C; Medina J; Bravo A; Mordoh J; Chernajovsky Y; Podhajcer OL
    Cancer Gene Ther; 1999; 6(4):358-66. PubMed ID: 10419054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.
    Trask TW; Trask RP; Aguilar-Cordova E; Shine HD; Wyde PR; Goodman JC; Hamilton WJ; Rojas-Martinez A; Chen SH; Woo SL; Grossman RG
    Mol Ther; 2000 Feb; 1(2):195-203. PubMed ID: 10933931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.